Physician profile
Lisa Elconin
NPI 1124095880
$6,196.67
in general payments reported to CMS, 2019-2025
41 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $213 · 2021: $508 · 2022: $918 · 2023: $1,018 · 2024: $1,049 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $846.65 | 2019-2025 | |
| Novo Nordisk INC | $682.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $623.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $556.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $474.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $443.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $370.73 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $225.97 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.89 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $160.65 | 2021-2024 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $144.13 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $142.71 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $131.70 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $94.15 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.60 | 2021-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $81.28 | 2019-2023 | Livalo, Seglentis |
| Idorsia Pharmaceuticals US INC | $81.21 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $76.15 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.46 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $65.52 | 2022-2025 | Givlaari |
| Amarin Pharma, INC. | $57.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $56.80 | 2019-2024 | Eliquis |
| Amneal Pharmaceuticals LLC | $45.54 | 2019 | |
| Corium, LLC | $44.73 | 2023 | Adlarity |
| Genentech USA, INC. | $43.14 | 2019-2022 | |
| Dexcom, INC. | $40.18 | 2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $33.27 | 2024-2025 | Uptravi, Opsumit |
| Bausch Health US, LLC | $32.25 | 2022-2023 | Aplenzin |
| Shield Therapeutics INC | $32.00 | 2023 | Accrufer |
| Eisai INC. | $29.97 | 2019 | |
| Circassia INC. | $29.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.73 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.07 | 2022 | |
| Therapeuticsmd, INC. | $23.53 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.41 | 2025 | Keveyis |
| Sumitomo Pharma America, INC. | $23.05 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $19.30 | 2023 | Heplisav-B |
| Seqirus USA INC | $18.94 | 2022 | |
| Ibsa Pharma INC. | $17.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $12.92 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Elconin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.